Rezurock is indicated for the treatment of patients aged 12 years and older with chronic graft-versus-host disease (chronic GVHD) who have received at least two prior lines of systemic therapy.

Rezurock treatment should be initiated and supervised by physicians experienced in the management of chronic GVHD.

Posology

The recommended dose of Rezurock is 200 mg administered orally once daily at approximately the same time with a meal.

Treatment should continue until disease progression or unacceptable toxicity.

A complete blood cell count and liver function test must be performed before initiating therapy with Rezurock.

Dose modification due to adverse reactions

Perform liver function tests at least monthly throughout treatment (see section 4.4).

The recommended Rezurock dose modifications for hepatotoxicity and other adverse reactions are provided in Table 1.

Table 1: Dose modifications for adverse reactions

ALT = alanine aminotransferase; AST = aspartate aminotransferase; ULN = upper limit of normal.

*Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, Grade 4 is life-threatening. Toxicity grades are in accordance with National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.3 (NCI-CTCAE v4.3). See section 4.8.

Dose modification due to drug interactions

Strong CYP3A4 inducers and Proton Pump Inhibitors decrease the exposure of belumosudil (see section 4.5).

Co-administration of belumosudil with drugs transported by OATP1B1 and BCRP substrates can lead to an increase in exposure of these concomitant drugs (e.g. rosuvastatin) (see section 4.5).

Strong CYP3A Inducers

Increase the dosage of Rezurock to 200 mg twice daily when co-administered with strong CYP3A inducers.

Proton Pump Inhibitors

Increase the dosage of Rezurock to 200 mg twice daily when co-administered with proton pump inhibitors.

OATP1B1/BCRP substrates

Consider switching to a drug less sensitive to OATP1B1 and BCRP inhibition when possible. If used together the dose of rosuvastatin should not exceed 5 mg once daily. Monitor patients closely for signs and symptoms of excessive exposure to the drugs that are substrates of OATP1B1 and BCRP.

Delayed or missed dose

If a dose is missed or delayed for less than 12 hours after the scheduled dose, the dose should be taken as soon as possible on the same day with a return to the normal schedule the following day.

If a dose is missed or delayed for more than 12 hours after the scheduled dose, the dose should be taken at the usual time the following day.

If a patient vomits following the intake of a dose, the next dose should be taken at the usual time the following day.

Patients should not take extra doses to make up the missed dose.

Special populations

Hepatic impairment

Dose modification is not recommended when administering belumosudil to patients with mild or moderate hepatic impairment (Child-Pugh A and B).

Belumosudil is not recommended in patients with severe hepatic impairment. The safety and efficacy of belumosudil in severe (Child-Pugh C) hepatic impairment has not been evaluated. For patients with pre-existing severe hepatic impairment (Child-Pugh C), consider the risks and potential benefits before initiating treatment with belumosudil (see section 5.2).

Monitor patients frequently for adverse reactions.

Renal impairment

No dose modification of Rezurock is required in patients with mild or moderate renal impairment (creatinine clearance ≥ 30 mL/min).

No data are available for patients with severe renal impairment (creatinine clearance < 30 mL/min) or for patients with end-stage renal disease on dialysis (see sections 5.1 and 5.2). Use with caution.

Elderly patients (≥ 65 years)

No additional dose adjustments are recommended for elderly patients (see sections 5.1 and 5.2).

Paediatric population

The posology is the same in adults and adolescents aged 12 to 18 years.

The safety and efficacy of Rezurock in children and adolescents aged below 12 years of age have not been established. No data are available (see section 5.1).

Method of administration

For oral use.

Rezurock should be taken at approximately the same time each day with a meal (see section 5.2).

The film-coated tablet should not be broken, crushed or chewed.

Pregnancy.

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Women of childbearing potential

Women of childbearing potential should be advised to avoid becoming pregnant while taking belumosudil and of the potential risk to a foetus, and to have a pregnancy test prior to starting treatment with belumosudil.

Women of childbearing potential must use a highly effective method of contraception during treatment with belumosudil and for at least one week after the last dose of belumosudil (see sections 4.6 and 5.3).

Male patients

Male patients with female partners of childbearing potential should be advised that their female partners should avoid becoming pregnant while taking belumosudil and of the potential risk to a foetus.

Males with female partners of childbearing potential must use a highly effective method of contraception during treatment with belumosudil and for at least a week after the last dose of belumosudil (see sections 4.6 and 5.3).

Breast-feeding

Breast-feeding is not recommended during treatment with belumosudil and for at least one week after the last dose (see section 4.6).

Hepatotoxicity

Increases in liver function tests were observed in clinical studies with belumosudil and generally occurred early during treatment with the incidence decreasing thereafter (see section 4.8). Liver function tests should be performed prior to the initiation of treatment with belumosudil and monitored at least monthly during treatment with belumosudil and the dose should be adjusted for ≥ Grade 2 toxicities (see section 4.2)

Effect of CYP3A inhibitors on belumosudil

The co-administration of multiple doses of itraconazole (a strong CYP3A inhibitor) did not alter exposure to belumosudil to any clinically relevant extent.

Effect of CYP3A inducers on belumosudil

The co-administration of multiple doses of rifampin (a strong CYP3A4 inducer) decreased belumosudil C_max by 59% and AUC by 72%. The co-administration of strong CYP3A4 inducers with belumosudil may decrease belumosudil exposure. Increase the dose of belumosudil to 200 mg twice daily (see section 4.2).

The co-administration of moderate CYP3A4 inducers e.g., efavirenz is predicted to have a reduced effect on belumosudil as compared to strong CYP3A4 inducers. The co-administration of moderate CYP3A4 inducers with belumosudil may decrease belumosudil exposure. No dose adjustment is recommended.

Effect of proton pump inhibitors on belumosudil

The co-administration of multiple doses of rabeprazole decreased belumosudil C_max by 87% and AUC by 80%. The co-administration of multiple doses of omeprazole decreased belumosudil C_max by 68% and AUC by 47%. The co-administration of proton pump inhibitors with belumosudil may decrease belumosudil exposure. Increase the dose of belumosudil to 200 mg twice daily (see section 4.2).

Effect of other gastric acid reducing agents on belumosudil

The co-administration of belumosudil with gastric acid reducing agents other than proton pump inhibitors may decrease belumosudil exposure. No dose adjustment is recommended, however belumosudil and the gastric acid reducing agent should be taken 12 hours apart.

In vitro studies

Effect of belumosudil on CYP3A substrates

The co-administration of belumosudil is predicted to increase midazolam (a sensitive CYP3A substrate) C_max and AUC approximately 1.3- and 1.5-fold, respectively. No dose adjustment is recommended.

The co-administration of belumosudil may increase exposure of sensitive CYP3A4 substrates with a narrow therapeutic index such as ciclosporin and tacrolimus. No dose adjustment is recommended.

Effect of belumosudil on CYP2C9 substrates

The co-administration of belumosudil is not expected to have clinically meaningful effect on the exposure of CYP2C9 substrates (such as warfarin).

Effect of belumosudil on CYP2C8 substrates

The co-administration of belumosudil is not expected to have clinically meaningful effect on the exposure of CYP2C8 substrates that are not an OATP1B1 substrate.

Effect of belumosudil on UGT1A1 substrates

Belumosudil is a weak inhibitor of UGT1A1, the clinical consequences are not known.

Transporters

Belumosudil is a substrate of P-gp. Belumosudil inhibits BCRP, P-gp, and OATP1B1. The co-administration of oral BCRP, P-gp and OATP1B1 substrates with belumosudil may increase the concentrations of the substrate drugs (such as digoxin and docetaxel).

The co-administration of belumosudil with drugs transported by OATP1B1 and BCRP can lead to an increase in exposure of these concomitant drugs (e.g. rosuvastatin) which may increase the risk of these substrate-related toxicities. Co-administration of belumosudil increases rosuvastatin C_max and AUC by 3.6 and 4.6-fold, respectively.

Pregnancy

There are no data on the use of belumosudil in pregnant women.

Belumosudil can cause foetal harm based on findings from animal studies (see section 5.3) and its mechanism of action. In pregnant rats and rabbits, oral administration of belumosudil resulted in maternal and/or foetal toxicity at doses below the recommended human dose. As a precautionary measure, belumosudil is contraindicated in pregnancy (see section 4.3).

Women of childbearing potential/Contraception in males and females

Women of childbearing potential should be informed that animal studies show belumosudil to be harmful to the developing foetus. Women of childbearing potential must have their pregnancy status verified prior to initiating treatment with belumosudil, and must use a reliable and highly effective method of contraception during treatment with belumosudil and for at least one week after the last dose of belumosudil. In case pregnancy should occur during treatment with belumosudil, a risk/benefit evaluation must be carried out on an individual basis with careful counselling regarding potential risks to the foetus (see sections 4.4 and 5.3).

Male patients with female partners of childbearing potential should be advised that their female partners should avoid becoming pregnant while taking belumosudil and of the potential risks to a foetus.

Male patients with female partners of childbearing potential must use a highly effective method of contraception during treatment and for at least one week after the last dose of belumosudil (see section 4.4).

Breast-feeding

It is unknown whether belumosudil or its metabolites are excreted in human milk. No data are available regarding the presence of belumosudil or its metabolites in animal or human milk or its effects on the breast-fed child, or on milk production. A risk to the infant cannot be excluded. Because of the potential for serious adverse reactions in a breast-fed child, breast-feeding should be discontinued during treatment with belumosudil and for at least one week after the last dose (see section 4.4).

Fertility

There are no human data on the effect of belumosudil on fertility. Based on findings from animal studies, belumosudil may impair male and female fertility at dose levels above the recommended clinical dose. The effects on fertility are reversible (see section 5.3).

Belumosudil may cause fatigue and dizziness (see section 4.8). Patients should be advised not to drive or operate machines if they experience these symptoms.

Summary of safety profile

The overall safety profile of belumosudil in chronic graft-versus-host-disease is based on data from 186 patients from two clinical trials, KD025-208 and KD025-213.

The most common adverse reactions (≥ 5%) were asthenia (21.0%), nausea (12.4%), liver function test abnormalities of elevation of AST (7.5%), elevation of ALT (7.0%) and elevation of GGT (4.8%), headache (8.6%), diarrhoea (7.0%) and musculoskeletal pain (5.9%). The most common Grade 3 or 4 adverse reaction (≥ 2%) was asthenia (2.7%). Serious adverse reactions were pneumonia (1.1%), cellulitis, infectious colitis, staphylococcal bacteraemia, diarrhoea, nausea, vomiting, microangiopathic haemolytic anaemia, multiple organ dysfunction syndrome and cGVHD (0.5% each).

The most common adverse reactions leading to discontinuation were nausea (2.4%) and headache (2.4%). Adverse reactions leading to dose interruption occurred in 9.6% of patients and were mainly investigations (3.6%), including ALT increased, GGT increased and blood creatine phosphokinase increased (1.2% each), and infections (2.4%).

Tabulated list of adverse reactions

Table 2 presents the frequency category for adverse reactions reported in the open-label clinical trials (studies KD025-208 and KD025-213) with belumosudil. A total of 186 adult patients with chronic GVHD were treated with belumosudil 200 mg once daily (N=83), 200 mg twice daily (N=82), or 400 mg once daily (N=21) (see section 5.1). The median duration of treatment of the 83 patients with 200 mg once daily belumosudil was 9.2 months (range 0.5 to 44.7 months) and in the 186 patients across the three dosing cohorts was 9.89 months (range 0.39 to 44.71 months).

The frequency of adverse reactions are defined as follows:

Very common: (≥ 1/10)

Common: (≥ 1/100 to <1/10)

Uncommon: (≥ 1/1000 to <1/100)

Rare: (≥ 1/10,000 to <1/1000)

Very rare: (<1/10,000)

Not known: (cannot be estimated from the available data)

Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

Table 2: Adverse reactions (≥ 2%) in patients with chronic GVHD who received belumosudil

Description of selected adverse reactions

Hepatobiliary disorders

Elevations of liver enzymes were reported in patients treated with belumosudil in clinical trials. In two randomised, open label, multi-centre clinical trials in patients with cGVHD (studies KD025-208 and KD025-213), any grade laboratory abnormalities of increased AST, increased ALT and increased GGT occurred in 7.5%, 7.0% and 4.8%, respectively, of patients receiving belumosudil. Grade ≥ 3 laboratory abnormalities of increased AST, increased ALT and increased GGT occurred in 1.6%, 1.1% and 1.1%, respectively, of patients receiving belumosudil. Events resolved with few drug discontinuations, drug interruptions or dose reductions. The events generally occurred early during belumosudil treatment with the incidence decreasing thereafter. For recommended dosage modifications following elevations of liver enzymes see section 4.2. For recommended monitoring of liver enzymes see section 4.4.

Blood and lymphatic disorders

In the randomised, open label, multi-centre clinical trials in patients with cGVHD (studies KD025-208 and KD025-213), any grade anaemia and leukopenia occurred in 3.2% and 4.8%, respectively, of patients receiving belumosudil. Grade ≥ 3 events of anaemia and leukopenia occurred in 0.5% and 1.6%, respectively, of patients receiving belumosudil. Grade 3 cytopenias were often associated with relapse of the underlying malignancy.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected new or serious adverse reactions via the Yellow Card Scheme. You can find information on this at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

No cases of overdose have been reported.

There is no specific experience in the management of belumosudil overdose in patients. There is no known antidote for overdoses with belumosudil. Single doses up to 1000 mg have been given with acceptable tolerability in healthy volunteers. Appropriate supportive treatment should be given.

Pharmacotherapeutic group: Immunosuppressants, selective immunosuppressants, ATC code: L04AA48.

Mechanism of action

Belumosudil is a potent and selective Rho-associated, coiled-coil containing protein kinase-2 (ROCK2) inhibitor that mediates signalling in immune cellular function and fibrotic pathways. In vivo, belumosudil has demonstrated activity in a variety of clinically relevant animal models of disease including chronic GVHD.

Pharmacodynamic effects

Cardiac Electrophysiology

At a dose of 5 times the recommended dose, belumosudil does not prolong the QT interval to any clinically relevant extent.

Clinical efficacy and safety

Two open-label Phase 2 studies (studies KD025-208 and KD025-213) were conducted in patients with chronic GVHD.

Study KD025-213

Study KD025-213 (N=131) was a randomized, open-label, multicentre study of belumosudil for treatment of patients with chronic GVHD. Patients were eligible for the study if they had received 2 to 5 prior lines of systemic therapy and required additional therapy. Patients received a stable dose of corticosteroids for two weeks prior to entry to the study. Patients were randomised 1:1 to receive belumosudil dosed orally at 200 mg once daily or 200 mg twice daily. Randomization was stratified according to prior cGVHD treatment with ibrutinib (yes/no) and severe cGVHD (yes/no).

Where patients were on a stable dose/schedule of standard of care therapies for chronic GVHD, concomitant use of these was permitted, including local and topical treatments and ECP. Transient increases in corticosteroid dosing (that did not exceed 1 mg/kg/day prednisone equivalent) were permitted for the treatment of cGVHD flare, but the dose must have been reduced back to the pre-randomization dose within 6 weeks. If the dose remained elevated for more than 6 weeks, this was considered a belumosudil treatment failure. More than 2 episodes of cGVHD flare that required increased corticosteroid therapy in the first 6 months of belumosudil treatment was also considered a belumosudil treatment failure. Initiation of one or more new systemic therapies for chronic GVHD indicated a new line of therapy and was classified as a treatment failure.

Of patients enrolled in the study, the median age was 55 years (range 21 to 77 years), 57% of patients were male and 85% were white. The majority (67%) of patients had severe cGVHD disease and 73% of patients were refractory to their last systemic therapy prior to enrolling in the study. The most common underlying malignancies leading to transplantation were acute myeloid leukaemia, acute lymphocytic leukaemia and myelodysplastic syndromes. The organs involved at baseline were skin (83%), joints/fascia (76%), eyes (74%), lung (36%), mouth (54%), oesophagus (24%), upper GI (17%), lower GI (10%) and liver (10%), and 51% of patients had 4 or more organs involved. The most common prior systemic therapy was corticosteroids (98%), followed by calcineurin inhibitors (tacrolimus 62% and sirolimus 47%), ECP (48%), ibrutinib (34%) and ruxolitinib (29%). The median prior lines of therapy was 3 (range 2-6).

The primary efficacy endpoint was the overall response rate (ORR), defined as the proportion of subjects who achieved a complete response or a partial response according to the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in chronic GVHD. Responses were assessed by investigators. Secondary endpoints included duration of response, changes in symptom burden/bother using the Lee Symptom Scale Score (LSS) and time to next treatment.

Study KD025-213 met its primary objective. For the 200 mg once daily dose, the ORR (data cut-off: 19-Aug-2020) was 74% (62-84%); 6% of patients achieved a CR and 68% of patients achieved a PR. Responses, including complete responses, were achieved across all organs involved (skin, eyes, joints/fascia, mouth, lung, oesophagus, upper GI, lower GI and liver). Duration of response (defined as the time from first ORR response to progression of disease in any organ measured in comparison to nadir, new systemic therapy, or death whichever comes first) was 8 weeks (95% CI 4-64 weeks).

Results for Study KD025-213 at the 200 mg once daily belumosudil dose are presented in Table 3.

Table 3: Best overall response rate and other efficacy results in Study KD025-213

CI = Confidence interval; K-M = Kaplan Meier; NR = Not reached.

For the 200 mg twice daily dose, the ORR was 77.3% (95% CI 65.3%, 86.7%) and the DOR (defined as the time from first ORR response to progression of disease in any organ measured in comparison to nadir, new systemic therapy, or death whichever comes first) was 8 weeks (95% CI 2-81 weeks).

Study KD025-208

Study KD025-208 (N=54) was a dose-escalation, open-label, multicentre study of belumosudil for treatment of patients with chronic GVHD who had received 1 to 3 prior lines of systemic therapy and required additional therapy. Belumosudil was administered orally at 200 mg once daily (N=17), 200 mg twice daily (N=16), or 400 mg once daily (N=21).

Where patients were on a stable dose/schedule of standard of care therapies for chronic GVHD, concomitant use of these was permitted, including corticosteroids and calcineurin inhibitors. Initiation of one or more new systemic therapies for chronic GVHD indicated a new line of therapy and was classified as a treatment failure.

Of patients enrolled in the study, the median age was 52 years (range 20 to 75 years), 63% of patients were male and 87% were white. The majority (78%) of patients had severe cGVHD disease and 73% of patients were refractory to their last systemic therapy prior to enrolling in the study. The most common underlying malignancies leading to transplantation were acute myeloid leukaemia, acute lymphocytic leukaemia and myelodysplastic syndromes. The organs involved at baseline were eyes (78%), skin (74%), mouth (65%), joints/fascia (63%), lung (32%), upper GI (15%), oesophagus (11%), lower GI (7%), and liver (4%), and 50% of patients had 4 or more organs involved. The most common prior systemic therapy was corticosteroids (100%), followed by calcineurin inhibitors (tacrolimus 48% and sirolimus 44%), rituximab (30%), and ECP (28%). The median number of prior lines of therapy was 2.5 (range 1-4).

The primary efficacy endpoint was the overall response rate (ORR), defined as the proportion of subjects who achieved a complete response or a partial response according to the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in chronic GVHD. Responses were assessed by investigators. Secondary endpoints included duration of response, failure free survival and time to next treatment.

Study KD025-208 met its primary objective. For the 200 mg once daily dose, the ORR was 64.7% (95% CI 38.3%, 85.8%). Responses (partial response) were achieved across all organs involved, there were no complete responses reported. Duration of response (defined as the time from first ORR response to progression of disease in any organ measured in comparison to nadir, new systemic therapy, or death whichever comes first) was 19 weeks (95% CI 7-128 weeks).

Safety and efficacy in older patients

Of the 186 patients with chronic GVHD in clinical studies of belumosudil, 25.8% were 65 years and older. No overall differences in safety or effectiveness of belumosudil were observed between these patients and younger patients.

Paediatric population

The Medicines and Healthcare Products Regulatory Agency has deferred the obligation to submit the results of studies with Rezurock.

Absorption

Median T_max of belumosudil across studies was approximately 3 hours. Following a single oral dose of belumosudil 200 mg, mean absorption (% coefficient of variation) was 64% (17%).

Effect of Food

In healthy subjects, the administration of a single 200 mg dose of belumosudil with a high-fat and high-calorie meal (800 to 1,000 calories with approximately 50% of total caloric content of the meal from fat) increased belumosudil C_max to 2.2 times that following fasted administration and AUC to 2 times that following fasted administration. Median T_max was delayed 0.5 hours.

The mean steady-state AUC (% coefficient of variation) observed in patients with chronic GVHD receiving 200 mg once daily administered with food was 22700 (48%) h• ng/mL; mean steady-state C_max was 2390 (44%) ng/mL. With once daily administration, steady-state concentrations of belumosudil were achieved with an accumulation ratio of 1.4.

Distribution

Pharmacokinetics were described by a two compartmental model with a distribution half-life of 1.8 h. Belumosudil volume of distribution of the central compartment (% coefficient of variation, CV) was 29.7 L (143%). In in vitro preparations, binding to human serum albumin was 99.9% and binding to human α 1-acid glycoprotein was 98.6%.

Biotransformation

Based on in vitro assessment, CYP3A4 was the predominant CYP isoform responsible for the metabolism of belumosudil, although CYP2C8, CYP2D6 and UGT1A9 contributed to a lesser extent.

Elimination

Population PK modelling results in chronic GVHD patients showed that belumosudil elimination half-life (% coefficient of variation, CV) was 19.0 h (39%). Belumosudil clearance (% coefficient of variation, CV) was 9.83 L/h (46%).

The Human Mass Balance study results indicated that faecal excretion is the major route of excretion (85% of the dose). Of the dose recovered in faeces, 30% was parent belumosudil. Less than 5% of the dose was recovered in urine.

Linearity/non-linearity of dose

Exposure to belumosudil (C_max and AUC) appears to be slightly greater than dose proportional over the 20 to 500 mg once daily dose range, but less than dose-proportional for doses above 500 mg in healthy subjects. In chronic GVHD subjects, the exposure increase between 200 and 400 mg is approximately proportional.

Special populations

No clinically relevant differences in belumosudil pharmacokinetics were observed with regard to age, race, sex, weight or renal impairment (mild or moderate; severe renal impairment has not been studied).

Hepatic impairment

In a single-dose hepatic impairment study, the exposure in subjects with mild (Child-Pugh class A) and moderate (Child-Pugh class B) hepatic impairment had exposure ≤ 1.5 times the exposure observed in normal subjects. C_max was not changed significantly by mild and moderate hepatic impairment. In subjects with severe hepatic impairment (Child-Pugh C), the AUC of belumosudil increased 4.21-fold while there was no apparent effect on its C_max (1.32-fold increase), relative to subjects with normal liver function.

Carcinogenicity studies have not been conducted with belumosudil.

Belumosudil was not mutagenic in an in vitro bacterial mutagenicity (Ames) assay. Belumosudil was not clastogenic in either an in vitro chromosome aberration assay in mammalian (CHO) cells or an in vivo mouse bone marrow micronucleus assay.

In a female rat fertility study, belumosudil was administered to female rats 14 days prior to mating and up to gestation day 7. Belumosudil had no effect on fertility or reproductive function of female rats at doses of 50, 150 or 275 mg/kg/day. However, in female rats at a dose of 275 mg/kg/day resulted in maternal toxicity and increased post-implantation loss/resorptions and decrease in the number of viable foetuses. The exposure (AUC) at the dose of 275 mg/kg/day is approximately 9.4 times the clinical exposure (AUC) at the maximum recommended dose of 200 mg daily.

In a male rat fertility study, belumosudil was administered to male rats 70 days prior to and throughout mating to non-treated female rats. Belumosudil had no effects on fertility or reproductive function in male rats at doses of 50 and 150 mg/kg/day. However, a dose of 275 mg/kg/day resulted in generalized toxicity, reduced male fertility, abnormal sperm findings (reduced motility, reduced concentration and increased percentage of abnormal sperm), and testes/epididymis organ changes. The exposure (AUC) at the dose of 275 mg/kg/day is approximately 8.6 times the clinical exposure at the maximum recommended dose of 200 mg daily.

Adverse changes in male and female reproductive organs also occurred in general toxicology studies; findings included spermatozoa degeneration at a belumosudil dose of 35 mg/kg/day in dogs and decreased follicular development in ovaries at 275 mg/kg/day in rats. Changes were partially or fully reversed during the recovery period. The exposure (AUC) at the doses of 35 mg/kg/day in dogs, and 275 mg/kg/day in rats is 0.5 times and 8-9 times, respectively, the clinical exposure at the recommended dose of 200 mg daily.

In pregnant rats, oral administration of belumosudil during the period of organogenesis resulted in maternal toxicity (reduced body weight gain and low food consumption) at doses ≥ 50 mg/kg/day. Foetal effects included decreased foetal weight at ≥ 150 mg/kg/day (approximately 3.9 times the human exposure at the recommended dose based on AUC).

In pregnant rabbits, oral administration of belumosudil during the peroid of organogenesis resulted in maternal toxicity (body weight loss, reduced body weight gain, low food consumption and mortality) at doses ≥ 125 mg/kg/day. Foetal effects included abortions, increased post-implantation loss, decreased percentage of live foetuses, decreased foetal body weight, and skeletal/external malformations in foetuses at doses ≥ 50 mg/kg/day (approximately 0.07 times the human exposure at the recommended dose based on AUC).

Tablet core

Microcrystalline cellulose

Hypromellose

Croscarmellose sodium

Colloidal silicon dioxide

Magnesium stearate

Tablet coating

Polyvinyl alcohol (E1203)

Polyethylene glycol (E1521)

Talc (E553b)

Titanium dioxide (E171)

Yellow iron oxide (E172)

Not applicable.

2 years

Do not store above 25° C.

Dispense to patient in original packaging only.

Store in the original package in order to protect from moisture.

Replace cap securely each time after opening. Do not discard desiccant.

High-density polyethylene bottle with a child-resistant closure and a silica gel desiccant in a pack size of 30 film-coated tablets.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.